- Home
- KURA vs SANA Comparison
KURA vs SANA Comparison
Compare KURA & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KURA
- SANA
- Stock Information
- Founded
- KURA 2014
- SANA 2018
- Country
- KURA United States
- SANA United States
- Employees
- KURA N/A
- SANA N/A
- Industry
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- SANA Medicinal Chemicals and Botanical Products
- Sector
- KURA Health Care
- SANA Health Care
- Exchange
- KURA Nasdaq
- SANA Nasdaq
- Market Cap
- KURA 592.7M
- SANA 519.8M
- IPO Year
- KURA N/A
- SANA 2021
- Fundamental
- Price
- KURA $6.38
- SANA $1.50
- Analyst Decision
- KURA Strong Buy
- SANA Strong Buy
- Analyst Count
- KURA 10
- SANA 5
- Target Price
- KURA $25.50
- SANA $9.50
- AVG Volume (30 Days)
- KURA 1.1M
- SANA 3.7M
- Earning Date
- KURA 05-01-2025
- SANA 05-07-2025
- Dividend Yield
- KURA N/A
- SANA N/A
- EPS Growth
- KURA N/A
- SANA N/A
- EPS
- KURA N/A
- SANA N/A
- Revenue
- KURA $53,883,000.00
- SANA N/A
- Revenue This Year
- KURA $13.15
- SANA N/A
- Revenue Next Year
- KURA $221.86
- SANA N/A
- P/E Ratio
- KURA N/A
- SANA N/A
- Revenue Growth
- KURA N/A
- SANA N/A
- 52 Week Low
- KURA $6.27
- SANA $1.49
- 52 Week High
- KURA $23.48
- SANA $10.50
- Technical
- Relative Strength Index (RSI)
- KURA 30.98
- SANA 28.89
- Support Level
- KURA $6.95
- SANA $2.18
- Resistance Level
- KURA $8.04
- SANA $2.43
- Average True Range (ATR)
- KURA 0.43
- SANA 0.27
- MACD
- KURA -0.07
- SANA -0.09
- Stochastic Oscillator
- KURA 6.21
- SANA 0.66
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.